Skip to content
Opens in a new window
Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma
30 October 2026

Georgina V Long PhD FRACP; ESMO 2026: Neoantigen mRNA Vaccine Significantly Delays Recurrence in Patients with Resected Melanoma

Audio Journal of Oncology Podcast

About
MADRID, Spain—Individualized vaccination as adjuvant therapy for patients with stage two to four resected melanoma has achieved positive and highly encouraging outcomes according to findings from the INTerpath-001: Phase 3 study reported at the European Society for Medical Oncology 2026 congress.

Patients in the study were randomized to treatment with the mRNA-based neoantigen therapy intismeran autogene added to standard immune checkpoint inhibitor adjuvant therapy, and compared with a control arm of patients receiving checkpoint inhibition alone.